PFS and correlative biomarker analysis from the phase 3 coBRIM study - European Medical Journal

PFS and correlative biomarker analysis from the phase 3 coBRIM study

Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Paolo A. Ascierto, MD, of Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Naples, Italy, discusses the median progression-free survival (PFS) evaluation and correlative biomarker analysis from coBRIM, a phase 3 study of cobimetinib plus vemurafenib in patients with advanced BRAF-mutated melanoma.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now